pharmaceutical investing Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1 Combination Trial
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
